Anti-Müllerian Hormone Measures Oocyte Quantity Rather Than Quality: Why Ovarian Reserve Tests Cannot Predict Natural Conception

Women receiving low Anti-Müllerian Hormone (AMH) test results are no longer being told they cannot conceive naturally. For years, a result below 1.0 ng/mL was widely interpreted as a closing reproductive window, prompting many to rush toward expensive fertility treatments.[3][4]

That clinical narrative has shifted dramatically as reproductive endocrinologists clarify what the hormone actually tracks. AMH measures the sheer size of a woman's remaining follicle pool, but it provides zero information about the genetic competence of those eggs.[4][8]

Because unassisted pregnancy requires only a single healthy egg to be released and fertilized in a given month, a smaller total reserve does not mathematically reduce the odds of a natural conception. Medical guidelines now explicitly advise against using AMH to predict spontaneous pregnancy.[2][4]

"An AMH test alone cannot diagnose PCOS or predict whether you'll be able to get pregnant," notes the National Library of Medicine's 2026 guidance. The distinction between egg quantity and egg quality is reshaping how fertility clinics counsel patients who are trying to conceive without medical intervention.[3]

The Mechanism: What AMH Actually Measures

Anti-Müllerian Hormone is a protein produced by the granulosa cells that line small, immature follicles inside the ovaries. Because these cells secrete the hormone continuously, its concentration in the bloodstream serves as a reliable proxy for the total number of resting follicles.[3][4]

A female fetus develops roughly seven million eggs, a number that drops to about one to two million by birth and 400,000 by puberty. Throughout a woman's reproductive life, she will ovulate approximately 450 times, while thousands of other follicles naturally degenerate through a process called atresia.[8]

As the overall follicle pool shrinks with age, the number of granulosa cells decreases, causing AMH levels to drop proportionally. A normal AMH range for a woman in her early thirties typically falls between 1.0 and 3.0 ng/mL, while levels below 1.0 ng/mL indicate diminished ovarian reserve.[4][8]

However, the hormone only reflects the inventory count of the warehouse, not the condition of the goods inside. "While ovarian reserve testing can be an indicator of egg count, it doesn't tell your provider how healthy those eggs are," the Cleveland Clinic explains in its 2023 clinical overview.[4]

The JAMA Cohort: Natural Conception Rates

The definitive evidence separating AMH from natural fertility emerged from a landmark 2017 study published in the Journal of the American Medical Association. Researchers led by Dr. Anne Steiner followed 981 women aged 30 to 44 who were attempting to conceive naturally.[1][6]

The prospective cohort study tracked participants who had been trying to get pregnant for three months or less, specifically excluding those with a known history of infertility. The investigators measured baseline AMH, follicle-stimulating hormone, and inhibin B to see if these biomarkers predicted success.[1][7]

The results fundamentally disrupted standard fertility assumptions across the medical community. Among women with severely low AMH levels—defined in the study as below 0.7 ng/mL—84 percent successfully conceived within 12 menstrual cycles without any medical intervention.[1][6]

Crucially, this success rate was not statistically different from the control group. Women in the cohort with normal AMH levels demonstrated a 75 percent cumulative conception rate over the same 12-month period, proving that a diminished reserve did not impede unassisted pregnancy.[1][6]

"Women with biomarkers suggesting decreased ovarian reserve did not have a lower predicated probability of conceiving by cycle 6 or 12," noted a 2021 clinical review by the fertility research group FACTS. The data confirmed that low AMH does not equate to infertility.[7]

Why Quantity Does Not Equal Quality

The biological reason behind the JAMA findings comes down to the mechanics of human ovulation. During a natural menstrual cycle, the ovaries typically mature and release just one dominant egg, regardless of whether the total reserve contains 10,000 or 100,000 resting follicles.[4][8]

If that single ovulated egg is chromosomally normal and capable of fertilization, conception can occur. A low AMH indicates that the ovaries have fewer total eggs to choose from, but it does not mean the egg selected for ovulation that month is defective.[4][8]

"Ovarian reserve and egg quality are related to reproductive ageing, but they are not the same biological concept," explains Slavica IVF in its 2026 clinical guidance. A smaller pool simply means the reproductive window will close sooner, not that the current cycle is compromised.[8]

This distinction is why reproductive endocrinologists urge patients not to view an AMH score as a pass-or-fail fertility grade. A 32-year-old woman with an AMH of 0.4 ng/mL has a severely diminished reserve for her age, but her remaining eggs likely possess the high genetic quality typical of her early thirties.[8]

The Role of Chronological Age

When evaluating a patient's ability to conceive naturally, chronological age remains the single most powerful predictor of success. As a woman ages, the proportion of her eggs that contain chromosomal abnormalities steadily increases, driving down the monthly probability of a viable pregnancy.[4][8]

This age-related decline in oocyte competence happens independently of the total follicle count. A 42-year-old woman with a robust AMH of 2.5 ng/mL has plenty of eggs remaining, but she will face significantly higher hurdles to natural conception than a 30-year-old with an AMH of 0.5 ng/mL.[4][8]

The American Society for Reproductive Medicine explicitly distinguishes oocyte quantity from oocyte quality in its practice committee documents. The society notes that age is considerably more informative than any blood biomarker when estimating natural reproductive success.[2][8]

Because egg quality cannot be measured by any current laboratory test, age serves as the only reliable proxy. Once a patient reaches 35, the rate of chromosomal errors accelerates, which is why clinical guidelines recommend seeking an infertility evaluation after six months of trying, rather than the standard twelve.[4]

When AMH Testing is Actually Useful

If AMH cannot predict natural conception, its primary clinical value lies in the realm of assisted reproductive technology. The hormone is an exceptionally accurate predictor of how a patient's ovaries will respond to the injectable stimulation medications used during in vitro fertilization.[4][8]

During an IVF cycle, the goal is to override the body's natural single-egg selection process and mature multiple follicles simultaneously. A high AMH level indicates that the ovaries contain a large cohort of recruitable follicles, meaning the patient is likely to yield a high number of eggs during retrieval.[4][8]

Conversely, a low AMH warns the reproductive endocrinologist that the ovaries will likely produce only a few eggs, even with maximum medication dosages. This allows clinics to tailor their stimulation protocols, manage patient expectations, and avoid dangerous complications like ovarian hyperstimulation syndrome.[4][8]

"Testing your AMH level helps your provider know what dose of fertility medicine you may need to get the best response," MedlinePlus advises. For patients freezing their eggs or undergoing IVF, the test is indispensable; for those trying at home, it often causes unnecessary anxiety.[3]

Clinical Guidelines and Next Steps

Major medical organizations have updated their diagnostic algorithms to reflect the science. The American College of Obstetricians and Gynecologists now cautions against using a single AMH measurement to predict time to pregnancy in women who have not been diagnosed with infertility.[2][8]

ASRM guidelines similarly state that ovarian reserve markers are poor independent predictors of natural reproductive potential. The society recommends that AMH testing be reserved for women who are already undergoing an infertility workup, planning for IVF, or facing medical treatments that threaten ovarian function.[2][8]

For patients who do discover a low AMH incidentally, the recommended action is not panic, but proactive planning. While the monthly odds of conception remain intact, the overall timeline to achieve a desired family size—especially if multiple children are planned—may be compressed.[8]

Physicians advise these patients to begin attempting conception without delay and to consult a specialist if pregnancy does not occur within six months. The ultimate message from the data is clear: a low ovarian reserve signals a shorter runway, but the plane can still take off.[5][8]